Immunai is a series b startup based in United States. 1 investor tracked on Brouky Intelligence. Data sourced from Brouky Intelligence.
About
An AI-powered biotechnology company that uses single-cell genomics to discover and develop novel therapeutics that reprogram the immune system.
Stage
series-b
Investors
1
See full investor history, risk signals & comparable companies
Brouky tracks 15,000+ startups with funding rounds, risk analysis, and AI-powered investor matching.
Subscribe to Brouky